Comprised of subject matter experts drawn from the Cell & Gene Therapy (CGT) and advanced therapies industries, the GeneSuites Technical Advisory Committee (TAC) evaluates and provides input on the design, technology, cGMP requirements, and technical details of GeneSuites facilities.

​

The TAC is integral to validate GeneSuites' High-Performance Shell and turnkey suite offerings as cGMP-capable solutions that effectively accelerate speed to market. By combining best practices in the industry, both GeneSuites and its TAC can enable life science companies to achieve commercialization quicker while minimizing risk.